EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers

Rutika Mehta, Samuel Rivero-Hinojosa, Farshid Dayyani iD, Jenifer Ferguson, Bushra Shariff, Vasily N Aushev, Griffin L Budde, J Bryce Ortiz iD, Giby V George, Shruti Sharma, Adham A Jurdi iD, Minetta C Liu und 2 weitere

Cancer · 01.01.2026 · 132 (1)

DOI: 10.1002/cncr.70242 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, online erschienen am 04.01.2026. Verfasst von Rutika Mehta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Stomach Neoplasms, Esophageal Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natera Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Circulating tumor DNA (ctDNA) is a valuable biomarker for assessing treatment response and molecular residual disease. In advanced esophageal and gastric cancer (gastroesophageal cancer [EGC]), ctDNA dynamics remain poorly understood. The authors investigated ctDNA in patients with advanced EGC to evaluate its clinical utility.

Methods

This was a multi‐institutional, retrospective analysis of 200 patients with recurrent/metastatic EGCs who underwent commercial ctDNA testing using a personalized, tumor‐informed assay (Signatera; Natera, Inc.). Patients were divided into cohort A ( N = 36; stage I–III with recurrence) or cohort B ( N = 164; metastatic at diagnosis). Longitudinal ctDNA dynamics were correlated with clinical and radiographic findings.

Results

In cohort A, 31 of 36 patients (86.1%) had ctDNA collected ≤90 days before recurrence; of these, 25 of 31 patients (80.65%) were ctDNA‐positive before recurrence. In cohort B, baseline ctDNA was available for 29 of 164 patients (17.68%), and all 29 were ctDNA‐positive. Among 52 patients who had on‐treatment ctDNA assessments, 62 treatment lines were analyzed ( N = 6 in cohort A; N = 46 in cohort B). All who remained ctDNA‐negative throughout treatment (Neg‐Neg) showed treatment benefit ( n = 6 of 6). Those who converted to ctDNA‐positive (Neg‐Pos) progressed ( n = 2 of 2). Among ctDNA‐positive patients (Pos‐Pos), 27 of 40 (67.5%) showed treatment benefit, whereas 13 of 40 (32.5%) progressed. Patients who cleared ctDNA (Pos‐Neg) had favorable outcomes (12 of 14 patients; 85.7%). A decrease >90% in ctDNA levels among Pos‐Pos patients was linked to superior progression‐fee survival. Grouping treatment lines into favorable (Neg‐Neg, Pos‐Neg, and Pos‐Pos with >90% decrease) versus unfavorable (Neg‐Pos and Pos‐Pos with a

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAStomach NeoplasmsEsophageal NeoplasmsNeoplasm Recurrence, LocalBiomarkers, TumorHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAged, 80 and overNeoplasm MetastasisAdultPrognosis

Stichwörter der Autor:innen

circulating tumor DNA (ctDNA)ctDNA dynamicsmetastatic gastroesophageal cancertreatment response

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York, USA.
  • Natera, Inc., Austin, Texas, USA.
  • Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, USA.
  • Department of Internal Medicine, H. Lee Moffitt Cancer Center, Tampa, Florida, USA.
  • Medical Oncology, The START Center for Cancer Care, San Antonio, Texas, USA.
  • Massachusetts General Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Farshid Dayyani, J Bryce Ortiz, Adham A Jurdi

Förderung

  • Natera Inc.

Zitieren

APA

Mehta, R., Rivero-Hinojosa, S., Dayyani, F., Ferguson, J., Shariff, B., Aushev, V. N., Budde, G. L., Ortiz, J. B., George, G. V., Sharma, S., Jurdi, A. A., Liu, M. C., Drengler, R. L., & Klempner, S. J. (2026). Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers. Cancer, 132(1). https://doi.org/10.1002/cncr.70242

Vancouver

Mehta R, Rivero-Hinojosa S, Dayyani F, Ferguson J, Shariff B, Aushev VN, et al. Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers. Cancer. 2026;132(1). doi:10.1002/cncr.70242

BibTeX
@article{Mehta2026,
  author = {Mehta, Rutika and Rivero-Hinojosa, Samuel and Dayyani, Farshid and Ferguson, Jenifer and Shariff, Bushra and Aushev, Vasily N and Budde, Griffin L and Ortiz, J Bryce and George, Giby V and Sharma, Shruti and Jurdi, Adham A and Liu, Minetta C and Drengler, Ronald L and Klempner, Samuel J},
  title = {Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {1},
  doi = {10.1002/cncr.70242}
}
Kostenlos starten →